vida: extract claims from 2026-pmc12673456-glp1-psychiatric-systematic-review

- Source: inbox/queue/2026-pmc12673456-glp1-psychiatric-systematic-review.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: structural
 sourcer: MDPI Nutrients
 supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction"]
 ---
 
 # No RCT evidence exists for GLP-1 receptor agonists in anorexia nervosa despite pharmacovigilance signals showing 4-7x elevated eating disorder risk
@@ -31,3 +31,10 @@ Review confirms 'no definitive evidence of the causal relationship between use o
 **Source:** PMC12694361 systematic review
 
 Systematic review (October 2025, MDPI Nutrients) provides strongest current evidence synthesis: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' Evidence quality characterized as 'low-to-moderate confidence throughout' with restrictive ED evidence 'scarce and inconclusive.' Most studies are 'short-term, narrowly sampled, and methodologically limited.'
+
+
+## Supporting Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Systematic review of 80 RCTs and large cohort studies confirms that 'most RCTs excluded individuals with moderate-to-severe mood disorders' and that evidence on restrictive eating disorders remains 'sparse.' The review recommends 'caution' in anorexia nervosa populations but provides no clinical trial evidence base for this recommendation, confirming the pharmacovigilance-only signal.

domains/health/glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive.md

@@ -11,7 +11,7 @@ sourced_from: health/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-ps
 scope: causal
 sourcer: MDPI Nutrients
 supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction"]
 ---
 
 # GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
@@ -45,3 +45,10 @@ Northwestern's AgRP neuron silencing mechanism provides the neurological explana
 **Source:** NPR, behavioral health specialist interviews
 
 Dr. DeCaro and Dr. Dennis focus exclusively on restrictive eating disorder risk (anorexia nervosa, atypical anorexia) with no discussion of binge eating disorder or purging pathways. The curator notes: 'No discussion of GI-induced purging specifically—the behavioral health experts interviewed focused entirely on restrictive disorders, not purging/bulimic pathway.' This confirms that clinical expert consensus identifies restrictive subtypes as the primary harm pathway.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Review confirms subtype-specific divergence: 'GLP-1RAs show promise for REDUCING binge eating — improvements in BES scores (-8.14 points vs. controls)' while simultaneously recommending 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns.' This documents the protective effect for BED and harmful signal for restrictive subtypes.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -80,3 +80,10 @@ Expert assessment that healthcare system is 'unprepared for this coming wave' of
 **Source:** APA Monitor on Psychology, July/August 2025
 
 APA Monitor coverage in July 2025 signals that the psychological professional community formally engaged with GLP-1 mental health effects 9 months before mainstream public awareness. Despite this early professional recognition, no APA clinical practice guidelines on GLP-1 prescribing or monitoring existed as of 2026, confirming the gap is structural capacity (lack of formal protocols and reimbursement) rather than clinical knowledge (practitioners were aware).
+
+
+## Supporting Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+Systematic review confirms that 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns' but provides no evidence that systematic screening is occurring. The review categorizes anhedonia and eating disorder risk as 'potential adverse outcomes' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' — not because effects don't exist, but because measurement infrastructure is absent. No validated hedonic measurement instrument (SHAPS) has been deployed in GLP-1 trials.

domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence-for-tonic-phasic-divergence.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: After years of multi-dose GLP-1 prescribing, no systematic dose-response study on psychiatric outcomes exists, creating a critical evidence gap for a mechanism with known dose-dependent effects
+confidence: experimental
+source: Sa et al., Diabetes Obesity and Metabolism 2026 — systematic review of 80 RCTs
+created: 2026-05-06
+title: Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
+agent: vida
+sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
+scope: structural
+sourcer: Sa et al.
+related: ["medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific"]
+---
+
+# Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
+
+This systematic review explicitly identifies the complete absence of human dose-response data on GLP-1 psychiatric effects as a major evidence gap. The review notes that preclinical evidence shows 'GLP-1 signaling exerts both anxiogenic and antidepressant effects, depending on dosage, exposure duration and the specific neural targets engaged.' Despite this mechanistic understanding, and despite years of clinical use at multiple dose levels (semaglutide 0.5mg, 1mg, 2mg; tirzepatide 2.5mg-15mg), no systematic dose-response study has been conducted on psychiatric outcomes. The review's mechanism section explains that GLP-1's 'activation of the HPA axis and its engagement of brain regions involved in emotion regulation' suggests dose-dependent effects, yet the human evidence base contains no data to test this hypothesis. This gap is particularly striking given that the tonic/phasic receptor occupancy hypothesis predicts fundamentally different psychiatric effects at weight-loss doses versus lower doses, but clinical trial infrastructure has not been deployed to measure this. The absence is structural: most RCTs excluded individuals with moderate-to-severe mood disorders, and 'short follow-up periods restrict insight into long-term psychiatric safety.' The review categorizes anhedonia as a 'potential adverse outcome' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse' — not because the effect doesn't exist, but because no validated hedonic measurement instrument (like SHAPS) has been systematically deployed in GLP-1 trials.

domains/health/glp1-rct-observational-divergence-small-depression-reduction-versus-195-percent-mdd-increase.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: The largest systematic evidence synthesis documents opposite psychiatric effects in controlled versus real-world settings, with RCT data showing benefit and observational data showing harm
+confidence: likely
+source: Sa et al., Diabetes Obesity and Metabolism 2026 — meta-analysis of 80 RCTs (107,860 participants) plus large cohort studies
+created: 2026-05-06
+title: GLP-1 RCT meta-analysis shows small but consistent depression reduction (SMD -0.12) while observational cohort data shows 195 percent increased MDD risk, creating a directional contradiction that requires methodological resolution
+agent: vida
+sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
+scope: correlational
+sourcer: Sa et al.
+related: ["medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
+---
+
+# GLP-1 RCT meta-analysis shows small but consistent depression reduction (SMD -0.12) while observational cohort data shows 195 percent increased MDD risk, creating a directional contradiction that requires methodological resolution
+
+This systematic review documents a fundamental directional contradiction in GLP-1 psychiatric evidence. The RCT meta-analysis of 80 trials covering 107,860 participants found 'small but statistically significant REDUCTION in depression rating scale scores (SMD ≈ -0.12, p < 0.01)' with consistent direction across trials. A post hoc analysis confirmed 'statistically significant but clinically negligible reduction in depressive symptoms' with treatment difference of -0.56. However, a large cohort study using post-marketing surveillance data found '195% increased risk of major depressive disorder' in obesity populations — a directional opposite. Medicare data showed 'no significant difference vs. SGLT2 inhibitors, reduced risk vs. DPP-4 inhibitors,' adding further complexity. The review does not resolve this contradiction but documents it explicitly. The divergence likely reflects methodological differences: RCTs excluded individuals with moderate-to-severe mood disorders ('high-risk populations routinely excluded'), had short follow-up periods, and measured depression as a secondary outcome using rating scales. Observational data captured real-world populations including those with psychiatric comorbidity, longer exposure durations, and clinical diagnoses rather than symptom scales. The review notes that 'most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' This evidence structure — consistent small benefit in controlled settings, large harm signal in observational data — is the core contradiction that within-individual cohort designs (like the Swedish Lancet Psychiatry study) are positioned to resolve.

domains/health/medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates.md

@@ -10,8 +10,16 @@ agent: vida
 scope: correlational
 sourcer: Stanford/Harvard ARISE Research Network
 related_claims: ["[[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]]"]
+related: ["medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials"]
 ---
 
 # Medical benchmark performance does not predict clinical safety as USMLE scores correlate only 0.61 with harm rates
 
 The NOHARM study found that safety performance (measured as severe harm rate across 100 real clinical cases) correlated only moderately with existing AI and medical benchmarks at r = 0.61-0.64. This means that a model's USMLE score or performance on other medical knowledge tests explains only 37-41% of the variance in clinical safety outcomes. The finding challenges the widespread practice of using benchmark performance as evidence of clinical safety — a practice employed by companies like OpenEvidence which markets its 100% USMLE score as a safety credential. The gap exists because medical exams test knowledge recall and reasoning on well-formed questions with clear answers, while clinical safety requires completeness (not missing necessary actions), appropriate risk stratification, and handling of ambiguous real-world presentations. A model can score perfectly on USMLE by correctly answering the questions asked while still producing high omission rates by failing to consider diagnoses or management options not explicitly prompted. The study tested 31 models spanning the performance spectrum, with best performers (Gemini 2.5 Flash, LiSA 1.0) achieving 11.8-14.6 severe errors per 100 cases and worst performers (o4 mini, GPT-4o mini) at 39.9-40.1 severe errors per 100 cases — a range that existing benchmarks fail to predict reliably.
+
+
+## Extending Evidence
+
+**Source:** Sa et al., Diabetes Obesity and Metabolism 2026
+
+GLP-1 psychiatric evidence provides parallel case: RCT meta-analysis (controlled evaluation setting) shows small depression reduction (SMD -0.12), while observational data (real-world setting) shows 195% increased MDD risk. Controlled evaluation performance does not predict real-world safety outcomes, just as USMLE scores don't predict clinical harm rates. Both document evaluation-reality divergence.

inbox/archive/health/2026-pmc12673456-glp1-psychiatric-systematic-review.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: research-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: high
 tags: [GLP-1, semaglutide, psychiatric-effects, systematic-review, anhedonia, depression, MDD, eating-disorders, dose-dependence, evidence-gaps]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content